Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 199c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of $1.30, $1.99 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $294.12 million versus the consensus estimate of $39.51 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• JPMorgan Downgrades Chewy Inc. (CHWY) to Neutral
• UBS Upgrades SD Guthrie (SDG:MK) to Buy